 Though clinical-stage biopharmaceutical firm Soleno Therapeutics NASDAQ: SLNO encountered more than its fair share of setbacks this year, it blitzed rival enterprises on Monday. Earlier this morning, management disclosed a securities purchase agreement with Nantahala Capital Management, Abingworth and Vivo Capital. 